Alamar Biosciences, Inc.
NASDAQ:ALMRBiotechnology
+$1.11 today
- Market cap
- $2.12B
- Beta
- 0.00
- P/E (TTM)
- -47.5
- EPS (TTM)
- -$0.45
Volume 0.53M
Average 0.38M
ALMR Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Alamar Biosciences, Inc.NASDAQ: ALMR
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development of $13.82M in Q2 FY2026
Q2 FY2026 research & development was $13.82M.
Context
- Research & development amounted to 50.5% of revenue in FY2025.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 37.47M USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 37.47M | — |
Research & Development vs competitors
How ALMR compares with its peers on the latest reported figures
- ALMR's FY2025 research & development of $37.47M is the 8th highest of the 9 companies compared; the peer median is $63.18M.
- Research & development amounts to 50.5% of revenue for ALMR, versus a peer median of 36.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $222.54M | -10.9% | -3.5% | 36.0% | |
| LTM Sep 2026 | $96.87M | -3.0% | +0.8% | 7.9% | |
| LTM Mar 2026 | $87.86M | -27.1% | -20.4% | 54.9% | |
| LTM Sep 2026 | $71.84M | -10.5% | -12.4% | 15.6% | |
| LTM Mar 2026 | $54.53M | -11.0% | -9.3% | 2944.3% | |
| LTM Mar 2026 | $41.33M | -11.2% | -6.2% | 274.8% | |
| LTM Mar 2026 | $40.3M | -12.6% | +4.1% | — | |
ALMRAlamar Biosciences, Inc. | FY2025 | $37.47M | — | — | 50.5% |
| LTM Mar 2026 | $22.48M | -43.6% | -11.4% | 26.1% | |
| Peer median (excluding ALMR) | $63.18M | -11.1% | -7.8% | 36.0% | |
Competitors are the stored peer set for ALMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 74.21M |
| Cost of Revenue | 32.51M |
| Gross Profit | 41.71M |
| Gross Margin | 56.2% |
| Research & Development | 37.47M |
| Selling, General & Admin | 35.57M |
| Operating Expenses | 73.04M |
| Depreciation & Amortization | 3.86M |
| EBITDA | (24.89M) |
| EBITDA Margin | -33.5% |
| Operating Income | (31.33M) |
| Operating Margin | -42.2% |
| Interest Income | 2.16M |
| Interest Expense | 401K |
| Other Income / Expenses | 2.18M |
| Income Before Tax | (29.15M) |
| Pre-Tax Margin | -39.3% |
| Income Tax Expense | 665K |
| Net Income | (29.82M) |
| Net Margin | -40.2% |
| EPS (Basic) | (0.45) |
| EPS (Diluted) | (0.45) |
| Weighted Avg Shares | 66.52M |
| Weighted Avg Shares (Diluted) | 66.52M |
Alamar Biosciences, Inc.
NASDAQ:ALMR
Intrinsic Alpha fair value
Locked
Current Price
$30.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.